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Abstract
Introduction—Physiological processes at the molecular level take place at precise
spatiotemporal scales, which vary from tissue to tissue and from one patient to another, implying
the need for the carriers that enable tunable release of therapeutics.
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Areas Covered—Classification of all drug release to intrinsic and extrinsic is proposed,
followed by the etymological clarification of the term “tunable” and its distinction from the term
“tailorable”. Tunability is defined as analogous to tuning a guitar string or a radio receiver to the
right frequency using a single knob. It implies changing a structural parameter along a continuous
quantitative scale and correlating it numerically with the release kinetics. Examples of tunable,
tailorable and environmentally responsive carriers are given, along with the parameters used to
achieve these levels of control.
Expert Opinion—Interdependence of multiple variables defining the carrier microstructure
obstructs the attempts to elucidate parameters that allow for the independent tuning of release
kinetics. Learning from the tunability of nanostructured materials and superstructured
metamaterials can be a fruitful source of inspiration in the quest for the new generation of tunable
release carriers. The greater intersection of traditional materials sciences and pharmacokinetic
perspectives could foster the development of more sophisticated mechanisms for tunable release.
Keywords
Drug Delivery; Release Kinetics; Tailorable Release; Tunable Release
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1. Introduction
The increasing incidence of chronic diseases coupled with the incentives to improve the
quality of life has attributed to the development of advanced biomaterials[1][2][3]. Over the
past several decades, metals, polymers, ceramics and bio-derived materials have been
extensively studied and used as medical implants. Such materials can be designed for a wide
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range of biomedical applications, e.g., controlled drug delivery devices, tissue engineering
constructs, vascular grafts and multiple other therapeutic, regenerative and/or diagnostic
platforms. However, the ability of materials scientists to fine-tune the structure of materials
to desired mechanical or electromagnetic properties has surpassed the ability to fine-tune
them to exhibit complex kinetics of release of therapeutic molecules.
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Overall, there is a need for the development of ever more sensitive and smarter controlled
release carriers in pharmaceutics. To terminate the drug release when the therapeutic goal
has been achieved and to trigger the release from the carrier only in the presence of a certain
disease marker are only some of the demands for the new generation of drug release carriers.
At a finer level, the drug release kinetic profiles could be designed for precise temporal
matching of the targeted physiological processes that facilitate healing on the molecular
scale. This would prevent systemic or local toxicity, ensuring patient safety while also
increasing the efficacy with which the device delivers its therapeutic payload.

Author Manuscript

Many biological processes take place at precise timescales. For example, the reaction of the
complement system to a foreign entity involves a cascade of processes, each of which is
preceded and anteceded by others at precise timescales. Sophisticated targeting of individual
processes in such a cascade necessitates the initiation of the therapeutic action through the
controlled release of the right molecular agent within a very specific time window. Another
example comes from wound healing (Fig. 1a), a physical response to injury that similarly
involves a multitude of processes, each of which occur within precise time windows.
Interfering with these processes with the intended therapeutic effect means that the timescale
of this interference must be precisely set to the right time windows. Bone remodeling is yet
another biological process divisible to individual stages (Fig. 1b), implying that an ideal
therapeutic interference with this process would also require a sequential, precisely
temporally tuned delivery of the right therapeutic agents. Targeted drug delivery in terms of
precise 3D location of the released drug would be greatly enriched if one such targeting
effect in the fourth, temporal dimension is achieved too.

Author Manuscript

Types of compounds traditionally delivered with the use of sustained release platforms since
the early days of controlled drug delivery devices are listed in Table 1. However, preclinical
optimizations of ideal release kinetics to individual pathological features on the molecular
scale have ceded place to “one size fits all” approach, where a single type of implant,
microstructurally speaking, is being supplied to the clinic, ignoring the fact that every
clinical case is unique and different from any other. Additionally, utilizing the therapeutic
role of small biomolecules and proteins on tissue regeneration may demand their controlled
release at precisely tunable timescales. Signaling molecules, including hormones, cytokines
and growth factors are included on this long list of compounds whose finely tuned delivery
from the kinetic standpoint would greatly facilitate the wound healing and tissue
regeneration processes.
The need for tunable release profiles is illustratable by the dichotomy between cortical and
cancellous bone. Namely, with the cortical bone being more compact and having a lower
remodeling rate than the more porous and vascularized cancellous bone, the ideal release
profiles should be faster and more intense in the treatment of cancellous bone. As one shifts
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from the surface of long bones to their marrow, one simultaneously moves in the direction of
decreasing compactness and an increasing soft tissue nature. The clearance rate of the
released drug would consequently decrease with the distance from the central axis of long
bones; the need for the tuning of the release rate to the right implant location naturally
follows from acknowledging this functionally gradient nature of bone. Sustained delivery of
pain medication from sutures and wound dressings has, likewise, demonstrated that no
single release profile fits all patients. Rather, in some cases the medication has to be
supplemented orally because of the insufficient dose delivered, whereas in other cases the
oral administration of opioid antagonists is necessary because of the adverse effects of the
systemic overdose[19]. These clinical circumstances imply that tunable release agents are
necessary to match the wide variety of analgesic needs of patients.
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Therefore, the variability of structure and properties of a single tissue depending on the
location as well as the variability of structure and properties of identical tissues in different
patients imply the demand for carriers whose release rates could be tuned by varying a
single parameter that defines the corresponding internal structure of the material across a
continuous range of values. In such a manner, carriers would be designed to deliver drugs to
tissues in a tunable fashion and accommodate directly to the ideal projected drug delivery
profiles for the given tissues and the patient. In theory, rapid prototyping of implants in
direct feedback with computerized axial tomography scans could thus be complemented
with setting of the properties of the implant material to achieve the exactly desired release
profile without resorting to qualitative modifications of the material. This qualitative
constancy, notwithstanding the kinetic versatility, would also minimize the number of
regulatory hurdles standing on the translational path. The applicative benefits of devising
tunable drug carriers are thus clearly numerous enough to justify the furthering of the
research on them.
2.1. Elementary classification: intrinsic vs. extrinsic control of the release
Kinetically controlled and tunable release of therapeutics from a carrier is attainable by
multiple means. Still, all of them could be roughly divided to two categories: intrinsic and
extrinsic. As shown in Fig. 2, in case of the intrinsic controlled release, the structure of the
carrier becomes modified to vary the release rates and amounts, whereas in case of the
extrinsic controlled release, either the environmental factors or the external, manual or
automatized control triggers the release and occasionally enables the tuning of its rate to the
desired kinetics. In what follows we will briefly mention the examples that belong to both,
albeit for the most part limiting the scope of this review to the intrinsically tunable carriers.
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2.2. Etymological clarification: tailorable vs. tunable
Confusion exists in the literature as to what the term “tunable” exactly means. Most
occurrences of this attribute are incorrect, given that they describe the mere ability of a
carrier to produce two or more distinct release profiles following the tweaking of its
structure or introducing a variation in the physicochemical environment surrounding it.
However, tunability, in the truer sense of the word, should be analogous to tuning a radio
receiver along a continuous range of frequencies to a desired radio station or tuning a guitar
string to the desired pitch. In other words, it should imply the correspondence between a
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continuous range of values of a specific structural parameter of the carrier and a similarly
continuous range of values of properties determining the release of the drug from the given
carrier.
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For the sake of convention, we will ascribe the attribute “tailorable” to the process of
controlling the release kinetics by means of introducing qualitative changes in the carrier.
We will ascribe the attribute “tunable” to the process of controlling the release kinetics by
varying the quantitative value of a parameter that defines the structure of the carrier on a
continuous scale. For example, if the size of particles loaded with a drug is reduced and such
a reduction entails an increased rate of release of the physisorbed drug as the result of
increased surface-to-volume ratio, one such effect could receive the attribute of “tunable”,
provided that the control over the particle size is possible within a more or less continuous
range and that a numerical correlation could be established between the particle size and the
release rate. Likewise, when the stirring rate is varied to tune the nanoparticle size of
coordination-metal polymeric particles within a wide range of values[20], such an effect,
albeit somewhat trivial, is tunable so long as this range is continuous and broad enough.
Changing the release profile by changing the chemical identity of the ligand, on the other
hand, does not constitute a tunable effect, even though it is frequently reported in the
literature as such. Since tailoring denotes the act of cutting and pasting different patches of
clothes, controlling the release by the presence or absence of certain particle components
can be seen as analogous to the act of tailoring.
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Fig. 2 schematically depicts this difference between tailoring and tuning. In the case of
tunable release, a particular compositional or structural parameter is tuned to give a desired
release profile, whereas in the case of tailorable release, adding or subtracting different
carrier components, analogous to copying and pasting different patches of clothes, is used to
modify the release profile. For example, the yielding of distinct release profiles upon the
qualitative modification of the phase composition of calcium phosphate nanoparticles as
carriers could be considered tailorable (Fig. 3a) [21]. In contrast, the tuning of the release of
vancomycin and ciprofloxacin to anywhere between zero hours and two weeks by changing
the weight ratio between two components of a hydroxyapatite cement, differing only in the
rate of transformation into apatite from the amorphous primary precipitate, presents an
authentic instance of the use of calcium phosphate nanoparticles as tunable release carriers
(Fig. 5a–b) [22].
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Another class of carriers which are often inappropriately named “tunable” are those whose
release kinetics takes different forms depending on a specific physicochemical parameter
that defines the conditions of their environment. Unlike the authentically tunable release
carriers, in which tunability originates from the intrinsic control over a specific structural,
compositional or synthesis parameter, in the case of such “smart” carriers, which release
their payload only upon receiving a specific environmental stimuli in the form of a disease
marker, the release kinetics is controlled extrinsically, as it is being caused by the indiscrete
variation of an environmental parameter. One could include in this category carriers whose
release is controlled by external effects, such as heat, light, magnetic field, ultrasound,
mechanical force, and electric current (Fig. 2).

Expert Opin Drug Deliv. Author manuscript; available in PMC 2016 December 16.

Uskoković and Ghosh

Page 5

2.3. Examples of tailorable carriers

Author Manuscript
Author Manuscript

A study in which various material/drug combinations for wound healing were tested came to
conclusion that incorporation of diclofenac into four fibrous wound dressing materials,
namely alginate, sodium carboxymethyl cellulose (Na-CMC), viscose rayon and
poly(ethylene terephthalate) (PET) renders kinetically distinct release profiles that could be
tailored for both chronic and acute wound treatments [23]. While alginate and Na-CMC
exhibited prolonged release and were found to be applicable for the treatment of chronic
wounds, viscose rayon and PET were suitable for acute wounds. Next, Fig. 3b illustrates a
difference in the release of vancomycin depending on the qualitative composition of cements
composed of poly(D, L-lactide-co-glycolide) (PLGA) and calcium phosphate nanoparticles.
While sole calcium phosphate caused the drug to be rapidly released, the addition of
mannitol or PLGA, be it as empty or loaded microspheres, extended it to various degrees.
Then, the release of fusion protein SH3-IGF-1 can be tailored by binding different peptides
to a hydrogel composed of hyaluronan and methylcellulose (HAMC) as the carrier. As can
be seen in Fig. 3c, the protein release is reduced in the presence of a strong binding peptide
(SBP) as compared to unbound HAMC and HAMC with a weak binding peptide (WBP).
Another example of tailorable release comes from the threefold acceleration of the release of
diltiazem hydrochloride from chitosan nanoparticles following the conjugation of chitosan
with L-leucine[24]. Adjusting the release of doxorubicin or vincristine to a desired rate by
modifying silk films as the carrier with carboxyl or sulfonate groups also belongs to the
category of tailored release (Fig. 3d).
2.4. Examples of devices with environmentally sensitive, stimuli-responsive release
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2.4.1. Carriers stimulated by the chemical conditions of their
microenvironment—Carriers capable of releasing their therapeutic payload only in the
presence of a particular disease marker present the first step toward the development of
theranostic drug delivery platforms. One example of “smart”, environmentally triggered
release is shown in Fig. 4a–b: the release rate of the anti-inflammatory drug, piroxicam
(PX), and of the negatively charged fluorescent sodium salt (FL) from polypyrrole (PPy)
nanoparticles is directly proportional to pH (Fig. 4a), whereas that of the positively charged
rhodamine 6G (R6G) is inversely proportional to pH (Fig. 4b). In Fig. 4c, gentamicin release
is shown to be triggered in the event of infection and the associated increase in the acidity of
the environment around the carrier. Such systems are attractive because of their potential to
obliterate the need for the prophylactic use of antibiotics and at the same time minimize the
systemic side effects. Also, the intracellular environment has a markedly higher redox
potential than the extracellular milieu, with the concentration of glutathionate inside the cell
(~ 10 mM) being three orders of magnitude higher than that outside the cell (~ 10 μM). The
cytosolic cleavage of disulfide or thioester bonds can be used as a trigger for the controlled
release of therapeutics, and one example is shown in Fig. 4d: as the concentration of
dithiothreitol, which cleaves the disulfide bond, is increased, so does the rate of release of
SN-38 from 2,6-bis(hydroxymethyl)aniline based polymeric nanoparticles increase too. The
concentration of an enzyme in the environment surrounding the carrier is another parameter
that could control the drug release rate: an example comes from the concentration of β-Dgalactosidase being directly proportional to the rate of release of nitric oxide from the
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enzymatically cleaved O2-(β-D-galactopyranosyl)1-(N-isopropylamino)diazen-1-ium-1,2diolate (Gal-IPA/NO) prodrug[28]
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2.4.2. Carriers stimulated by the external physical signal—A special class of
materials capable of having the release triggered by a change in a specific environmental
parameter are those in which such a change is being implemented not spontaneously, by a
biological process, but by the clinical operator. In such a case, the material responds to an
optical, magnetic, thermal or acoustic signal from an external device. PPy scaffolds, for
example, can exhibit tunable release by controlling the magnitude of electrical stimulation
applied to the polymer, which causes an increase in the interplanar spacing in the inverse
opal structure of PPy and the release of the intercalated drug [32]. Calcium alginate
hydrogels also enable the tunability of the drug release by controlling the electric field
strength. In one study, the release of folic acid increased from 13 to 18 to 25 to 31 % after
the first 30 min of immersion as the electric field strength increased from 0 to 0.5 to 1 to 5
V[33]. The release of Texas-red-conjugated bovine serum albumin (BSA) from gelatinous
microspheres incorporating thermoresponsive poly(N-isopropylacrylamide-co-acrylamide)
(PNIPAm-co-AAm) can be tuned by controlling the degree of deswelling, which itself is
controllable by temperature: from 20 to 100 % after 30 min as the temperature increased
from 22 to 42 °C[34]. The drug release with thermoresponsive polymers need not always
increase with temperature, as exemplified by the release of fluorescent 1anilinonaphthalene-8-sulfonic acid from polystyrene-block-poly(N-isopropylacrylamide)block-polystyrene (PS-b-PNIPAm-bPS) nanoparticles decreasing from 10 – 15 % after 3.6 h
at 25 °C to 4 – 8 % after the same time at 45 °C, i.e., above the cloud point temperature of
the PNIPAm[35].
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In a nanomachine domain, the concentration of Nile blue was made precisely tunable by
varying the rotation speed of nanoparticles in a nanomotor composed of a plasmonic, trilayered Au/Ni/Au nanorod as a rotor, a 200 nm thick magnetic film of Au/Ni/Cr as the
bearing and microelectrodes as the stator [36]. Specifically, the release rate of Nile blue
bound to the surface of plasmonic nanorods by incubation in a solution monotonically
increased with the rotation speed of the nanorods. This speed was controllable using the
electric voltage applied to the quadruple microelectrodes in the device.
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Then, a continuous increase in the magnetic field intensity in the 0 – 250 mT range linearly
increased the amount of released docetaxel from a battery-less MEMS device composed of a
drug reservoir wrapped up in a magnetic membrane made up of iron oxide nanoparticles
dispersed in a polydimethylsiloxane (PDMS) matrix[37]. Ultrasound irradiation has not been
controlled in intensity so as to produce tunable release profiles, but the use of on/off
modulation of the field to control dosing was noted in the literature: for example, the release
of rhodamine B from polystyrene-PDMS block co-polymeric nanofibers would be halted
without the field and induced at a constant rate when the field is switched on[38]. Similar
on/off modulations of photothermal, continuous-wave near-infrared laser irradiation allowed
a precise control of the amount of released doxorubicin from mesoporous copper sulfide
nanoparticles capped with hyaluronic acid to be achieved[39].
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A limited number of intrinsic structural parameters has been used to control drug release
rates in a tunable fashion. For example, porosity can be tuned to control the drug release;
one example comes from a study in which an increase in the pore size from 15 to 43 to 95
nm in an oxidized porous silicon carrier gradually increased the release rate of daunorubicin
(Fig. 5c) [40]. Similarly, the increase of the pore size of hollow silicon microspheres from 15
to 25 to 50 nm entailed a directly proportional increase in the release rate of quantum dots
from these microspheres [41]. Control over the current density and anodization time in the
40 – 60 mA/cm2 and 5 – 10 s range allowed for tuning the porosity of mesoporous silicon
from 53 to 60 to 72 % and the corresponding release of α-chymotrypsinogen from 3 to 45 to
85 % after 24 h [42].
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The crosslinking ratio in a polymer, typically controlled with the molar ratio between the
monomer and the cross-linker in the synthesis stage, has been frequently used to control the
diffusion coefficient of the drug entrapped within the polymer matrix and the rate of its
release into the environment. As for the tunable effect, increasing the crosslinking ratio of
calcium alginate in the 0.3 – 1.3 range proportionally decreased the amount of released folic
acid[33]. Then, increasing the crosslinking ratio of gelatin in starch/gelatin microspheres
from 0 to 12.5 to 25 % using glutaraldehyde decreased the released amount of methylene
blue from 99 to 70 to 68 % after 24 h[43]. Also, controlling the concentration of the crosslinker, 3,3′-ethylidene-bis(N-vinyl-2-pyrrolidone) (EBVP), in the 0.15 – 0.20 % range
allowed the release of niacin to be made tunable to anywhere between 5 and 20 h[44].
Interestingly, no changes in crosslinking outside this range had an effect on the drug release,
illustrating the limitations of this type of drug release control. In fact, it appears that
crosslinking degree ranges in which the tunable release effect is achievable are often narrow
and different depending on whether the release is short- or long-term. For example,
increasing the crosslinking degree in gelatin scaffolds from 0 to 23.7 % had no long-term (7
– 21 days) effect on the release of mitomycin C, even though it did have a threefold effect on
the decrease of the released amount after 24 h[45]. Finally, although the crosslinking degree
usually inversely relates to the water ingression and the drug diffusion and release rates,
opposite effects are frequently found in the literature. Thus, because the concentration of
active norbornene and thiol sites that bind the drug dropped with crosslinking, an increase in
the molecular weight of a poly(ethylene glycol) (PEG) hydrogel led to an increase in the
release rate of BSA: 40 and 60 % after 7 days for 2.5 and 4 kDa, respectively[46]. The same
effect explains why an increase in the crosslinking density of both chain- and step-grown
PEG caused a monotonous increase in the rate of release of BSA[47].
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Crosslinking can be the key parameter for tuning the release rate of drugs not only from
hydrogels, but from vitreous and elastomeric polymers too. For example, an increased
acrylation of trimethylene carbonate (TMC) elastomer and the corresponding decrease in the
ratio between TMC and D,L-lactide (DLLA) in their copolymer from 100:0 to 50:50,
indicating a more efficient crosslinking reaction, gradually increased the release of BSA
from 0 to 13 to 20 to 35 % after 40 days of the release time[48]. In this case, the
fundamental understanding of the process is technically easier because the rate-limiting step
is usually diffusion and occasionally osmosis, given that the effects of polymer swelling and
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erosion have a lesser effect on the release kinetics than in hydrogels. Diffusion of the solute
through the polymeric matrix is, of course, dependent on a plenty of other parameters, many
of which affect or are indirectly affected by crosslinking, including porosity, tortuosity, pore
connectivity, the hydrodynamic radius of the solute, hydrophobicity and polarity of the
polymer relative to the solute, the potential for hydrogen or van de Waals bonding between
the solute and the polymer, solute concentration gradient as the driving force for diffusion,
distribution of the repeat units in a polymer, geometry of the polymeric implant,
crystallinity, end group character and identity, chain defects and rigidity, et cetera; however,
not all of them are readily tunable in a sense in which this term is being used in this study.

Author Manuscript
Author Manuscript

The characteristic U-shaped degradation profile of PLGA as a function of LA/GA ratio[49]
has been frequently used to tune the release rate of drugs entrapped in PLGA as a function
of the weight ratio of these two monomers [50]. The release of thyrotropin releasing
hormone from PLGA microspheres increased with the increase in the GA content of the
polymer in the LA/GA ratio range from 50/50 to 100/0 [27]. Varying the LA/GA ratio from
70/30 to 90/10 while keeping other parameters constant decreased mitomycin-C release
from 70 to 30 wt.% after three months of release [52]. Likewise, lowering the feed ratio
between acrylamide (AAm) and (r)-α-acryloyloxy-β,β-dimethyl-γ-butyrolactone (DBA) in
a thermoresponsive copolymer decreased the rate of release of dexamethasone from 100 %
after a week for AAm/DBA = 5.25 to 15 % for AAm/DBA = 0.9[53]. The drug release from
electrospun polymeric fibers composed of polycaprolactone (PCL) and PLGA was also
made tunable by controlling the weight ratio between the two polymeric components [54].
Specifically, anti-HIV drug Tenofovir disoproxil was released faster at larger PCL contents
and more sustainably at larger PLGA contents. Also, micelles made of the block copolymer
composed of poly(ethylene glycol)-b-poly(lactic acid) (PEG-b-PLA) and PLA-b-PNIPAm
displayed a reduced release of ibuprofen as the content of PLA-b-PNIPAm increased [55].
Tuning the release as a function of the weight ratio between the two components of a carrier
is often the consequence of their different affinity for the drug, and one example comes from
the tunability of the release of recombinant human insulin-like growth factor 1 (rhIGF-1):
with rhIGF-1 binding more intensely to more biodegradable kerateine (KTN) than to less
biodegradable keratose (KOS), increasing the KTN/KOS weight ratio in a polymer increased
the rate of release of rhIGF-1[56]. The release was tunable within the 10 – 70 % range after
7 days, as defined by the release from pure KTN (10 %) and pure KOS (70 %), respectively.
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Still, although polymeric microspheres have been used as drug delivery carriers since the
1980s [58], the effects other than variations in the bulk composition and crosslinking ratio
have been rarely used for tunable release purposes. Controlling the thickness of the
polymeric film deposited over a drug reservoir can produce finely tuned release profiles[59];
however, this concept has been rarely ever translated to polymeric particle systems. Yet,
there are notable examples. For example, hollow composite gold/polymeric microcapsules
were 3D printed and the variation in the weight ratio of PLGA in the precursor solution from
0.5 to 5 wt.% controlled the capsule thickness and allowed the release of horseradish
peroxidase to be tuned to profiles shown in Fig. 5d. Also, hybrid PLGA/TiO2 microspheres
were fabricated using droplet-based microfluidics [60] and their surface texture was varied
by changing the mass ratio between titanium tetraisopropoxide (TTIP) and PLGA in the
dispersed phase. The higher the content of TTIP, the deeper the wrinkles and the faster the
Expert Opin Drug Deliv. Author manuscript; available in PMC 2016 December 16.
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drug release, a phenomenon which was attributed to a larger specific surface area leading to
a more rapid release of Tanshinone IIA as the drug. The degree of oxidation of
carboxymethyl cellulose microspheres with periodate was used to increase the release of
doxorubicin from 15 to 20 to 25 % as the oxidation degree increased from 9 to 17 to 35 %,
respectively[61]. The use of multiple other, finer polymer microparticle properties, - e.g.,
surface texture and chemistry, core/shell size/thickness, self-assembly features, etc. - is
expected to open up a whole new avenue in controlled drug release research.
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Other effects are also noted in the literature. Changing the degree of substitution of
deoxycholic acid in nanoparticles based on hyaluronic and deoxycholic acid conjugates
(HA-DOCA) from 5.9 to 7.6 to 9.4 changed the released amount of doxorubicin from 49 to
58 to 70 %[62]. Changing the particle size of magnesium carbonate from 25 – 50 to 75 –
100 to > 200 μm on average decreased the amount of released ibuprofen after 24 h, albeit
within a very narrow range, from 98 to 93 to 87 % [63]. The effect of the drug on the
structure of the carrier is never to be underestimated either, as the result of which the
concentration of the drug loaded into the carrier can often be used as a parameter to produce
tunable release profiles. One example comes from the increase in the released percentage of
the loaded dexamethasone paralleling an increase in the amount of the drug present in PCL/
silk fibroin nanoparticles as the carrier[64]. The release rate of doxorubicin from liposomes
similarly increased in parallel with the increase in the concentration of the encapsulated drug
and was made tunable using drug-to-lipid ratio as the control parameter[65]. The opposite
effect was observed in the case of loading HA-DOCA nanoparticles with different amounts
of doxorubicin: as the content of the drug in the carrier increased, the cumulative rate of the
release of the drug decreased (71 vs. 42 vs. 32 % after 24 h for 5, 10 and 20 wt.% loadings,
respectively)[62]. Such a disparity between the effects of technically identical parameters
illustrates the complexity of understanding and controlling the mechanisms of drug release
in general. Tunability achievable in a system with a specific drug/carrier combination may
be obliterated when the identity of the drug changes. One example comes from the
aforementioned tunable release of rhIGF-1 from KOS/KTN polymer, impossible to repeat
with another growth factor, recombinant human bone morphogenetic protein 2, or with an
antibiotic, ciprofloxacin[56]. Finally, Table 2 lists some of the patented carriers with
intrinsically tunable release properties. Table 3 provides a summary of the carriers referred
to in the text and of their categorization based on two major groups - intrinsic vs. extrinsic and two subgroups: tunable vs. tailorable and smart vs. manual, respectively (Fig. 2).

3. Expert Opinion
Author Manuscript

A central problem in the elucidation of parameters that could be used as “magic knobs” and
allow the drug release to be made intrinsically tunable is the inevitable entanglement of
variables defining the microstructure of the carrier. Changing one of these parameters is
bound to have an effect on other parameters, which may affect the release in an uncontrolled
manner and deter the tunable effect. For example, increasing the size of sucrose acetate
isobutyrate microsphere depots at first decreased the release rate of risperidone because of a
lesser particle surface area conducive to drug diffusion, but then increased it at even larger
particle sizes because of the larger porosity of the large particles[77]. Increasing the particle
size also does not only lower the specific surface area of the material, but also lowers the
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particle curvature and, thus, the surface energy, affecting particle-particle interaction, surface
binding and release of the drug, and the diffusion of the drug across the particle/solution
interface. Thus, although increased surface area of a flat surface directly translates to
increased released rate[78], increased surface area in a particulate system comes at the cost
of increased surface tension and compaction of the crystalline order at the particle surface,
which can act as a barrier to the release. Still, the medical need for such carriers is obvious
and its fueling the drive for the discovery is expected to overcome these fundamental
challenges and ambiguities. The ease, the elegance and the practical appeal of using a single
parameter to control the release rate as opposed to compromising between a multitude
thereof will also be a crucial contributor to the development of a new generation of
intrinsically tunable release carriers.

Author Manuscript
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Much has been said about the necessity for the input of materials scientists on devising more
advanced drug delivery platforms. However, the ability to control and theoretically predict
physicochemical properties of materials in a tunable manner still greatly surpasses the
ability to control and model their drug release properties. Insufficient versatility and inferior
stimuli-response sophistication of drug delivery devices compared to those of electronic
devices, the majority of which owe their function to the tunability of one or more of their
components, speaks in favor of this disparity. For example, today we know that
nanomaterials exhibit a markedly broader variety of potential properties than their bulk
counterparts, and tunability is one of their hallmarks. Owing to the quantum confinement
effect, the size of semiconducting particles at the nanoscale can be controlled to tune their
bandgap and, thus, the photon emission frequency to the desired value[79]. Simple
variations of graphene nanoribbon width, density or the doping level also allow for the
tunability of the bandgap and the corresponding metal–oxide–semiconductor field-effect
transistor properties[80][81][82]. Albeit having an insignificant effect in many other 2D
materials, including MoS2, a precise control over the number of deposited monoatomic
layers of phosphorene gives a precise control over the magnitude of the transport gap of the
material[83]. Plasmon resonance in gold nanostructures could be tuned by varying the
particle diameter[84], aspect ratio[85], thickness in a layer[86], et cetera. Sophisticated
superstructures, such as photonic crystals and metamaterials, also allow for the tunability of
optical properties through a control over their geometric features and translational
symmetry[87][88]. An unexplored, albeit bold question is if the tunability that typifies the
quantum properties of nanoparticles could be translated to the tunability of drug release
profiles.

Author Manuscript

Magnetic ceramics are instructive in terms of the intrinsic tunability of properties. By
controlling the distribution of cations at octahedral and tetrahedral sites of the spinel lattice
of ferrites, more than one of their magnetic properties, ranging from susceptibility to
permeability to Neel temperature to coercivity to remanence, can be tuned[89]. Variation of
the stoichiometric ratio between a couple of metallic dopants at the A site of the ABO3
perovskite structure of nanostructured manganites, e.g., x in La1−xSrxMnO3+δ, can be
employed to vary their Curie temperature and adjust it to the hyperthermically or
thermoblastically targeted tissue in magnetic cancer therapies[90]. Controlling a similar
stoichiometric parameter x, though defining Co/Ni molar ratio in magneto-dielectric ferrite,
BaSrCo2−xNixFe12O22, allows for the simultaneous tuning of the narrowband reflection
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reduction in a wide microwave frequency range at low x and high Co contents and of the
wideband transmittance attenuation in a similarly wide frequency range at high x and high
Ni contents[91]. Atomic layer engineering has also enabled the tuning of an array of
properties and transitions in alloys and ceramics depending on the atomically precise doping
levels and deposited geometries, ranging from 1D ribbons and strings to nanoladders to
sheets and films with an atomically defined thickness[92][93]. The question is whether
similar materials, methods and structural effects could be employed to yield tunable release
profiles too.
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This question may be the starting point for the expansion of the repertoire of materials with
tunable release properties. Traditionally, polymers have been the main choice for tunable
release agents because of the ease with which this control be intrinsically achieved using
parameters such as monomeric unit ratio, crosslinking ratio, etc. Until recently, it was
thought that calcium phosphates, like most ceramics, did not have the potential for
controllable release, let alone tunable. However, this was refuted with the development of
self-setting pastes in which the release of antibiotics could be modeled with simplistic
equations allowing for the prediction of release properties depending on a single, easily
controllable compositional parameter[22]. As far as the externally triggered release
platforms are concerned, piezoelectric and magnetostrictive materials, deforming in direct
proportionality with the intensity of the applied electric[94] or magnetic[95] fields,
respectively, and potentially releasing the captured drug in a kinetically controllable fashion,
present another class of ceramics that could be investigated for tunable delivery. Nanotubes,
e.g. boron nitride[96], or composites with polymers[97] present particularly attractive
subclasses of such materials owing to their proven drug loading and release capabilities.
Electrically responsive polymers[98] will also offer a whole new avenue in the utilization of
the proposed effects. Therefore, it is important that research aiming to discover new
materials for controlled release continues. Along the way, therapeutic synergies emerging
from the carrier properties other than those enabling the tunable release are expected to be
derivable by serendipity, if not by design.

Author Manuscript

One such diversification of the types of materials capable of exhibiting tunable release may
go hand-in-hand with the distancing from the now classical tissue engineering paradigm of
devising platforms that would regenerate, but not augment the replaced tissues. Thinking in
this bold direction and engaging in the use of materials whose therapeutic effects may be
due to their moderate toxicity and invasiveness of biophysical structures (every therapy is
conditioned upon the creation of a wound) may bring us closer to other advanced concepts
in the intrinsically tunable drug delivery. One of them would be the use of particle
aggregation degrees through the control of surface chemistry and charge. Another direction
worth exploring belongs to the exploitation of transitory, metastable, non-equilibrium states
for the kinetic control of release patterns. Polymorphic transitions have been used to mediate
drug release [99], but no tunable effects have been reported so far. Particle shell-to-core
volume ratio is another parameter that has been used to produce different release profiles;
however, the correlation between this parameter and release rate was rather volatile, not
allowing for the tunable effect [100].
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Finally, although the division to extrinsic/intrinsic and tunable/tailorable release carriers was
introduced to clarify the perspective on them, it is expected that, as ever, conditions for the
creation of the most prolific systems would be set on the grounds where the boundaries
crush and multiple concepts merge into one.
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Five bulleted summary points
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•

The fact that many biological processes take place at precise timescales
implies that ideal therapeutic platforms would be capable of achieving
a sequential, precisely temporally tuned delivery of the right
therapeutic agents.

•

Etymological clarification of the term “tunable” and its distinction from
the term “tailorable” is provided: in the case of intrinsically tunable
release, a particular compositional or structural parameter is tuned to
give a desired release profile, whereas in the case of intrinsically
tailorable release, adding or subtracting different carrier components is
used to modify the release profile.

•

Tunability can also be achieved extrinsically, being caused by the
indiscrete variation of an environmental parameter; included in this
category are carriers whose release is controlled by a specific disease
marker and carriers whose release is controlled by external effects, e.g.,
heat, light, magnetic field, ultrasound, mechanical force, and electric
current.

•

A central problem in the elucidation of parameters that could be used
as “magic knobs” that allow the drug release to be made intrinsically
tunable is the inevitable entanglement of variables defining the
microstructure of the carrier.

•

Identical parameters often exert diametrically opposite effects on drug
release in different carriers, illustrating the complexity of
understanding and controlling the mechanisms of drug release in
general.
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Fig. 1.

Timelines outlining successive stages in the processes of wound healing (a) and bone
remodeling (b). Reprinted with permissions from (b) Ref. [4] and (a) Ref. [5]. © 2011
O’Loughlin A, O’Brien T. Published in [5] under CC BY-NC-SA 3.0 license. Available
from: http://dx.doi.org/10.5772/19070.
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Fig. 2.
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Four types of kinetically controlled drug release. Two intrinsic types of control (a, b) can be
either tailorable (a) if the rate of release (k) is directly proportional to a particular
microstructural or compositional parameter of the carrier (A), or tunable (b) if the release is
controlled by adding or subtracting different components of the carrier. Two extrinsic types
of tunable release can be either smart, environmental (c) if the rate of release directly
corresponds to the concentration of a chemical or biochemical marker in the environment
surrounding the carrier or (d) manual if the rate of release is proportional to the intensity of
an electromagnetic or acoustic signal produced by an externally operated device. A in the
image refers to the microstructure or composition of the carrier, not the amount or
concentration of the loaded drug. The three curves at the bottom refer to three kinetically
distinct drug release profiles corresponding to the three different states of A.
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Different release profiles of: (a) bovine serum albumin depending on the qualitative nature
of the mesoporous calcium phosphate carrier; (b) vancomycin depending on the qualitative,
not quantitative change in the cement composition; (c) SH3-IGF-1 from HAMC depending
on whether the hydrogel is bound to a weak binding peptide (WBP) or to a strong binding
peptide (SBP); (d) doxorubicin depending on the qualitative modification of silk films as
carriers. Reprinted with permissions from Refs. [21] (a), [25](b), [26](c), and [27] (d).
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Fig. 4.

pH-triggered release of PX, FL (a) and R6G (b) from PPy nanoparticles. (c) pH-responsive
release of gentamicin from PEO-based polymeric nanoparticles covalently grafted onto
titanium surface and functionalized with the antibiotic. (d) redox-responsive release of the
antineoplastic drug, SN-38 from aniline-based polymeric nanoparticles. Reprinted with
permission from Refs. [29] [30] and [31].
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(a) Release of vancomycin from calcium phosphate pastes being tunable depending on the
weight ratio between two of its components, HAP1 and HAP2. The linear function of the
release rate versus the given weight ratio is shown in (b). (c) Release of daunorubicin from a
silica-based drug delivery carrier with different nanopore sizes. (d) Release of horseradish
peroxidase from gold-nanorod/PLGA microcapsules depending on the amount of PLGA in
the precursor solution and the resulting microcapsule thickness. Reprinted with permission
from Refs. [22] (a–b), [40] (c), and [57] (d).
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Types of drugs delivered with the controlled release and the associated pharmaceutical product names.
Delivered type of molecule

Pharmaceutical product

Reference

Anti-inflammatory drugs

Surodex

[6]

Corticosteroids

Ozurdex®, Retisert®, Iluvien®

[7]

Anticancer chemotherapeutics

Gliadel, ThermoDox, Decapeptyl®, Trelstar™

[8], [9],

Contraceptives

Norplant, Jadelle

[10]

Analgesics

DepoDur®, EXPAREL®

[11]

Antipsychotics

Risperdal

Consta™

[12]

Author Manuscript

Opioids

MS-Contin, Duragesic® (Fentanyl), Butrans®

[13]

Opioid antagonists

Vivitrol™

[14]

Antivirals

Vitrasert

[15]

Antibiotics

To bone: Palacos® G (gentamicin), Cemex® Genta (gentamicin), Simplex® P
(tobramycin), Combalt® G-HV (gentamicin), Samrtset® GHV (gentamicin), and
Versabond®; as oral tablets: Moxatag® (amoxicillin), Augmentin® XR (amoxicillin/
clavulanate potassium) and Cipro XR (ciprofloxacin)

[16], [17], [18]
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Examples of intrinsically tunable release carriers with intellectual property rights.
Material

Filing date

Author Manuscript

Control parameter

Reference

Organosiloxane-Poly(ethylene glycol) (PEG)

1988

Amount of the water-in-oil emulsion mixed in
with the elastomer-forming composition

[66]

Alpha-cyclodextrin and PEG-poly(propylene glycol)-PEG

2001

Copolymer weight ratio

[67]

Polyurethane coating

2002

Duration of the low-energy plasma
polymerization process

[68]

Poly(D, L-lactide-co-glycolide) (PLGA)-Hyaluronic acid
(HA)

2007

Ratio of the hydrophilic (HA) to the
hydrophobic matrix (PLGA)

[69]

PLGA coating

2008

Weight percent of acetone in acetone/methyl
ethyl ketone spraying solution containing 2 wt.
% polymer

[70]

Polycaprolactone (PCL)-PLGA core-sheath fibers

2009

Ratio between the feed rate of the inner (PCL)
and outer (PLGA) portion solutions during
electrospinning

[71]

PCL coating

2009

PCL molecular weight in the 10 – 80 kDa range

[72]

Hyaluronan and Methylcellulose (HAMC)

2010

MC content in HAMC, drug particle size

[73]

Hydroxyethylmethacrylate (HEMA)-chloroformate

2012

Conjugation degree of the prodrug to polymeric
carrier moieties

[74]

Polystyrene-polyisobutylene

2015

Drug particle size, the weight ratio of volatile
solvents in the solvent mixture
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Table 3
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Summary of the drug delivery carriers mentioned in the text and their categorization based on two major
groups (intrinsic/extrinsic) and two subgroups (tunable/tailorable and smart/manual) described in Fig. 2, along
with the key parameters for controlling the release kinetics.
Drug release type

Tunable

Author Manuscript

Material

Control parameter

Reference

Silicon

Porosity

[40], [41], [42]

Calcium alginate, Starch-gelatin, Gelatin, Polyethylene glycol (PEG), Trimethylene
carbonate (TMC)-D,L-lactide (DLLA)

Crosslinking degree

[33], [43],
[45], [46], [48]

Polyethylene glycol (PEG)

Molecular weight,

[46]

Poly(D, L-lactide-co-glycolide) (PLGA)

LA/GA ratio

[76], [49],
[50], [52]

Acrylamide (AAm)-(r)-α-acryloyloxy-β,β-dimethyl-γ-butyrolactone (DBA)

Feed ratio

[53]

Polycaprolactone (PCL), PLGA, PEG-b-PLA, PLA-b-PNIPAm, Kerateine (KTN)/
keratose (KOS), Gold/PLGA

Polymer content

[54], [55],
[56], [57]

Kerateine (KTN)/keratose (KOS)

Drug identity

[56]

PLGA/titania

Polymer-metal mass

[60]

Carboxymethyl cellulose

Degree of oxidation

[61]

Hyaluronic and deoxycholic acid conjugates (HA-DOCA)

Degree of substitution, Drug
content

[62]

Magnesium carbonate

Particle size

[63]

PCL/silk fibroin

Drug content

[64]

Alginate, Sodium carboxymethyl cellulose (Na-CMC), Viscose Rayon and Poly(ethylene
terephthalate) (PET)

Different material combinations

[23]

Calcium phosphate

Phase composition, addition of
the drug or of poly(D, Llactide-co-glycolide) (PLGA)

[21], [25]

Hyaluronan and methylcellulose (HAMC)

Binding of peptides

[26]

Chitosan

Conjugation of L-leucine

[24]

Silk

Modification by carboxyl or
sulfonate groups

[27]

Polypyrrole (PPy), Polyethylene oxide/titanium

pH

[29], [30]

2,6-bis(hydroxymethyl)aniline-based polymers

Cytosolic cleavage of disulfide
or thioester bonds

[31]

O2-(β-D-galactopyranosyl)1-(N-isopropylamino)diazen-1-ium-1,2-diolate (Gal-IPA/NO)

Enzyme concentration

[28]

PPy, Calcium alginate

Electric field strength

[32], [33]

Gold/Nickel/Gold-Gold/Nickel/Chromium nanomotor

Rotation speed

[36]

Gelatin-PNIPAm-co-AAm

Temperature

[34]

Polydimethylsiloxane/magnetite

Magnetic field intensity

[37]

Polystyrene-PDMS block co-polymers

Ultrasound irradiation on/off
modulation

[38]

Hyaluronic acid-copper sulfide

Photo thermal laser irradiation
on/off modulations

[39]

Intrinsic

Tailorable
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Smart

Manual
Extrinsic
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